Log In
Print
BCIQ
Print
Print this Print this
 

MGD010

  Manage Alerts
Collapse Summary General Information
Company MacroGenics Inc.
DescriptionBispecific antibody against CD32B and CD79b molecule immunoglobulin-associated beta (CD79B; B29) developed using Dual-Affinity Re-Targeting (DART) technology
Molecular Target CD79b molecule immunoglobulin-associated beta (CD79B) (B29)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Autoimmune (unspecified)
Indication DetailsTreat autoimmune diseases
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today